Photo: Alexander Utkin
Nacimbio holding, Rostec State Corporation, has got an Eurasian patent on the proprietary formulation of immunoglobulin G to be used for COVID-19 treatment. COVID-globulin drug developed on its basis can prevent the progress of severe complications caused by coronavirus disease. The patent will protect the domestic technology against unfair competition.
The effect of COVID-globulin is based on the passive immunization concept – due to increased concentration of specific antibodies to the disease agent in the patient’s blood, the immune system is enabled to respond the infection properly. The antibodies are bound with a protein on the virus surface preventing the virus from penetrating cells and, thus, block virus propagation in the body.
COVID-globulin is a unique product developed by our researchers that was released when the pandemic was in full swing. The new product has been added to a family of new drugs produced from blood plasma using the company’s know-how. The know-how provides virus-safe and effective products due to the inclusion of several additional purification stages. The Eurasian patent will protect the immunoglobulin against unfair competition,” said Aleksandr Nazarov, Deputy General Director of Rostec.
